Although this up to half reference indicates that is one of the T&C's of the grant so either the grant drops back to US$144.5m (being half of a US$289m capital cost), there's been capital cost increases beyond the US$289m estimate from 2023 Scoping study work (quite likely) or items of phase 2 are brought back within scope of phase 1 increasing the phase 1 capital cost to US$332m.
Overall the funding gap is still massively smaller than it was, but larger than the $8m figure in the earlier post because the grant would appear to be capped at 50% of the overall cost.
- Forums
- ASX - By Stock
- E25
- Ann: E25 HPMSM project selected for US$166M DoE Grant
E25
element 25 limited
Add to My Watchlist
0.00%
!
22.5¢

Ann: E25 HPMSM project selected for US$166M DoE Grant, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.43M |
Open | High | Low | Value | Volume |
22.5¢ | 22.5¢ | 21.5¢ | $21.94K | 100.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2779 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 62609 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2779 | 0.215 |
3 | 28857 | 0.210 |
2 | 8107 | 0.205 |
7 | 59405 | 0.200 |
3 | 13077 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.225 | 62609 | 2 |
0.230 | 72958 | 1 |
0.235 | 24800 | 2 |
0.240 | 252084 | 2 |
0.245 | 21276 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
E25 (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online